Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Theravance Biopharma's annualized net income for the quarter that ended in Mar. 2026 was €-17.07 Mil. Theravance Biopharma's average shareholder tangible equity for the quarter that ended in Mar. 2026 was €252.38 Mil. Therefore, Theravance Biopharma's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -6.76%.
The historical rank and industry rank for Theravance Biopharma's Return-on-Tangible-Equity or its related term are showing as below:
FRA:0TB'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -677.87 Med: -29.04 Max: 1689.74
Current: 47.3
During the past 13 years, Theravance Biopharma's highest Return-on-Tangible-Equity was 1,689.74%. The lowest was -677.87%. And the median was -29.04%.
FRA:0TB's Return-on-Tangible-Equity is ranked better than 95% of 1199
companies
in the Biotechnology industry
Industry Median: -42.4
vs FRA:0TB: 47.30
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Theravance Biopharma Return-on-Tangible-Equity Related Terms
Theravance Biopharma Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Theravance Biopharma's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:0TB vs ABUS, SANA, ANNX: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Theravance Biopharma's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theravance Biopharma Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Theravance Biopharma's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Theravance Biopharma's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -6.76% mean?
Theravance Biopharma (FRA:0TB) has a Return-on-Tangible-Equity of -6.76% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Theravance Biopharma and its competitors. According to the industry distribution chart, Theravance Biopharma ranks #60 out of 1199 companies in the Biotechnology industry, placing it in the top 5%.
Is Theravance Biopharma's Return-on-Tangible-Equity too high?
Theravance Biopharma's current Return-on-Tangible-Equity is -6.76%. Based on the distribution chart, Theravance Biopharma ranks #60 out of 1199 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Theravance Biopharma has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Theravance Biopharma's Return-on-Tangible-Equity compare to ABUS and SANA?
According to the Biotechnology industry distribution chart, Theravance Biopharma ranks #60 out of 1199 companies for Return-on-Tangible-Equity. This places Theravance Biopharma in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Theravance Biopharma and its competitors. Theravance Biopharma's current Return-on-Tangible-Equity is -6.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theravance Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Theravance Biopharma (FRA:0TB) is currently considered Modestly Undervalued. The stock's GF Value™ is €16.18, compared to a current price of €14.60 — trading 9.8% below its estimated fair value. The current Return-on-Tangible-Equity is -6.76%. Theravance Biopharma's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Theravance Biopharma (FRA:0TB), the current Return-on-Tangible-Equity is -6.76% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Theravance Biopharma (FRA:0TB) Overvalued in 2026?
Based on GuruFocus' analysis, Theravance Biopharma stock appears to be undervalued.
The current stock price of €14.60 is trading 9.8% below its estimated GF Value™ of €16.18.
GuruFocus considers Theravance Biopharma to be Modestly Undervalued.
Key valuation signals for FRA:0TB:
Return-on-Tangible-Equity: -6.76%
GF Value™: €16.18 vs. price of €14.60 (9.8% below fair value)
No single metric tells the full story. See the FRA:0TB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
72GF Score
Get the complete analysis for FRA:0TB
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:0TB has been successfully added to your 
